VEGFR2
Failed Trial Suggests Circulating Tumor DNA Monitoring Not as Universally Applicable as Hoped
Premium
Investigators stressed that their results don't mean that ctDNA monitoring shouldn't be pursued in advanced cancer settings but that they offer a cautionary tale.